Summit Therapeutics (SMMT) Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued?
AstraZeneca, Daiichi Sankyo and Summit Therapeutics (SMMT) have agreed to test Datroway with ivonescimab in multiple cancers, beginning with a Phase III trial in first line triple negative breast cancer.
The latest collaboration news lands after an active few weeks for Summit Therapeutics, including an equity investment from AstraZeneca at a conversion price of US$18.36 and additional clinical tie ups around ivonescimab across gastrointestinal and other tumor types. At a recent share price of US$16.76, the stock has a 7 day share price return of 7.33% and a 90 day share price return of 5.18%. The 1 year total shareholder return is down 21.82%, while the 3 year total shareholder return is more than 8 times, a mix that indicates strong longer term performance alongside some cooling in recent months.
Scan beyond Summit Therapeutics and this AstraZeneca partnership by reviewing a curated set of oncology-focused small and mid caps in our 35 healthcare AI stocks.
After a sharp three year run and a pullback over the past year, Summit Therapeutics now sits between those who see most of the gains already banked and those who think the real upside is still ahead.
Most Popular Narrative: 43% Undervalued
On Simply Wall St’s most followed view, Summit Therapeutics screens as materially undervalued, with a fair value estimate of about $29.21 against a last close near $16.76. This puts the current price well below that narrative line in the sand.
The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.
See why 4 investors see Summit Therapeutics as 43% undervalued.
Result: Fair Value of $29.21 (UNDERVALUED)
Still, the single asset focus on ivonescimab and the ongoing net loss of US$856.1 million mean trial setbacks or regulatory pushback could quickly flip the Summit Therapeutics narrative.
Find out about the key risks to this Summit Therapeutics narrative.
Next Steps
Mixed feelings about Summit Therapeutics after recent moves and valuation signals. If you want to act while the story is still forming, weigh both sides of the ledger by checking the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Summit Therapeutics?
If you are serious about building a stronger portfolio, do not stop at Summit Therapeutics. Use the Simply Wall St screener to hunt for opportunities that fit your style before others move first.
- Target potential mispricing by reviewing companies that screen as high quality and potentially overlooked in the 31 high quality undervalued stocks.
- Strengthen your income stream by checking out a curated set of higher yielding opportunities in the 7 dividend fortresses.
- Dial down portfolio risk by focusing on businesses that pass strict balance sheet and fundamentals checks in the list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com